CD274 and esophageal squamous cell carcinoma: Randomized trials comparing first-line immunochemotherapy with chemotherapy in ESCC were identified and evaluated association of platinum plus paclitaxel (TP) or fluoropyrimidine (PF) chemotherapy regimen, stratified by PD-L1 expression levels, with progression-free survival (PFS) and overall survival (OS) benefits.